Abstract: The invention relates to an isolated proteinaceous particle comprising a core of perform and/or granzyme, the core being surrounded by a glycoprotein shell comprising thrombospondin-1 (TSP-1) or a fragment thereof, a variant thereof or an orthologue thereof. The invention further relates to nn engineered proteinaceous particle comprising a core of perform and/or granzyme, the core being surrounded by a glycoprotein shell comprising a thrombospondin protein, or a fragment thereof, a variant thereof or an orthologue thereof, wherein the granzyme and/or the thrombospondin is genetically modified. Further related materials, medical uses and manufacture are also contemplated.

Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.

Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.

Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.

Abstract: The present invention relates to a method of identifying candidate compounds useful as chemotherapeutics or anti-infective compounds or anti-inflammatory drugs. This method involves providing a plurality of test compounds. The plurality of test compounds are incubated with human Regulatory T (Treg) cells expressing Disc-Large Homo log 1 (Dlgh1) or in which Dlgh1 is suppressed, where the Treg cells have an immunological synapse (IS). Test compounds which inhibit Dlgh1 expression, recruitment to the IS, and/or activity in the Treg cells are identified as candidate compounds potentially useful as chemotherapeutics or anti-infective compounds. Test compounds which enhance Dlgh1 recruitment to the IS and/or activity in the Treg cells are identified as candidate compounds potentially useful as anti-inflammatory drugs. The present invention also relates to methods of treating inflammatory conditions, cancers, and infectious diseases in a subject, as well as methods of inhibiting Treg cell activity.

Abstract: Disclosed is a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis. Specifically, the invention relates to a method of treating an immunological disorder or atherosclerosis in a patient comprising treating blood from the patient, or a defined component of said blood, with an inhibitor of PKC-theta ex vivo and then re-administering the treated blood to the patient.

Abstract: A method of purifying LFA-3 using affinity chromatography. Purified LFA-3 is useful for quantitating or separating out CD-2-containing cells.

Abstract: A micelle of an adhesion protein which naturally includes a phosphatidylinositol lipid anchor, the micelle being capable of binding multivalently to a plurality of target molecules on a cell surface; where the adhesion protein is LFA-3, the LFA-3 micelles can be administered to a patient to inhibit binding of activated T-cells to other cells.